Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 47%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb has demonstrated increased confidence in its pipeline, with risk-adjusted sales projections for milvexian and iber/mezi significantly raised to $1.2 billion and $3.6 billion respectively for 2033, reflecting strong potential in the stroke prevention and multiple myeloma markets. The firm has benefitted from favorable guidance ahead of consensus estimates, which has alleviated market concerns and prompted enthusiasm around its CELMoD offerings from notable expertise in the oncology field. Additionally, a robust dividend of approximately $2.50, along with prudent cost management and a resilient Growth Portfolio, further contributes to a positive financial outlook for the company.

Bears say

Bristol-Myers Squibb faces significant potential revenue and earnings impacts due to delays in regulatory approval and product launches, which can hinder its financial growth. The company's forward EV/EBITDA multiple remains below the average of its peers, indicating a potential undervaluation relative to the sector. Additionally, ongoing risks associated with clinical trials, such as regulatory hurdles and evolving market dynamics, may threaten the firm's ability to introduce successful new products, further complicating its financial outlook.

Bristol-Myers (BMY) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 47% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 15 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.